Categories Earnings, Other Industries

Valeant Pharmaceuticals International Inc. Q4 2017 earnings snapshot

Canada’s Valeant Pharmaceuticals posted a 9.9% decline in its fourth quarter 2017 revenue, driven by the impact of divestitures and lower volumes in the U.S. Diversified Products segment. Revenue declined to $2.16 billion from $2.4 billion in the second quarter of 2016.

The company swung to profit in the quarter compared to a loss a year ago, helped by increase in the benefit from income taxes. Net income attributable to Valeant was $513 million compared to a loss of $515 million in the same period in 2016.

Outlook

For the full year 2018, Valeant Pharmaceuticals expects revenues in the range of $8.10 billion to  $8.30 billion, while full year adjusted EBITDA is expected in the range of $3.05 billion to $3.20 billion. Valeant will continue to address its debt, as well as reduce expenses as it has been doing since first quarter of 2016, said the CEO Joseph Papa.

Valeant Pharmaceuticals fourth quarter 2017 earnings results

Most Popular

Important takeaways from Paychex’s (PAYX) Q2 2025 earnings report

Paychex Inc. (NASDAQ: PAYX), a leading provider of human resources and payroll services, reported better-than-expected revenue and profit for the second quarter of fiscal 2025, sending the stock higher soon

Lamb Weston’s (LW) challenges may not end soon, a few points to note

Shares of Lamb Weston Holdings, Inc. (NYSE: LW) turned red in mid-day trade on Friday. The stock has dropped 19% in the past one month. The company delivered disappointing results

CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%

Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top